http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Jean M Larson ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Jean M Larson ),( Anna Tavakkoli ),( Walter E Drane ),( Phillip P Toskes ),( Baharak Moshiree ) 대한소화관운동학회 2010 Journal of Neurogastroenterology and Motility (JNM Vol.16 No.4
Background/Aims Current therapy for gastroparesis with prokinetic agents is limited by options and side effects. One macrolide, erythromycin (ERY), is associated with possible sudden cardiac death from QT prolongation due to P450 iso-enzyme inhibition. An alternative, azithromycin (AZI), lacks P450 inhibition. We compared the effect on gastric emptying half-times (t½) between AZI and ERY in patients diagnosed with gastroparesis by gastric emptying scintigraphy. Methods Patients stopped medications known to affect gastric emptying prior to the study, and then ingested 1 scrambled egg meal labeled with 18.5-37 MBq of technetium-99m sulfur colloid followed by continuous imaging for 120 minutes, at 1 minute per frame. A simple linear fit was applied to the rate of gastric emptying, and gastric emptying t½ was calculated (normal =45-90 minutes). At 75-80 minutes, if the stomach had clearly not emptied, patients were given either ERY (n=60) or AZI (n=60) 250 mg IV and a new post-treatment gastric emptying t½ was calculated. Results Comparison of gastric emptying t½ showed a similar positive effect (mean gastric emptying t½ for AZI=10.4±7.2 minutes; mean gastric emptying t½ for ERY=11.9±8.4 minutes; p=0.30). Conclusions AZI is equivalent to ERY in accelerating the gastric emptying of adult patients with gastroparesis. Given the longer duration of action, better side effect profile and lack of P450 interaction for AZI as compared with ERY, further research should evaluate the long term effectiveness and safety of AZI as a gastroparesis treatment. (J Neurogastroenterol Motil 2010;16:407-413)
-
Park, Wooram,Chen, Jeane,Cho, Soojeong,Park, Sin-jung,Larson, Andrew C.,Na, Kun,Kim, Dong-Hyun American Chemical Society 2016 ACS APPLIED MATERIALS & INTERFACES Vol.8 No.20
<P>Transcatheter hepatic intra-arterial (IA) injection has been considered as an effective targeted delivery technique for hepatocellular carcinoma (HCC). Recently, drug eluting beads (DEB) were developed for transcatheter IA delivery to HCC. However, the conventional DEB has offered relatively modest survival benefits. It can be difficult to control drug loading/release from DEB and to monitor selective delivery to the targeted tumors. Embolized DEBs in hepatic arteries frequently induce hypoxic and low pH conditions, promoting cancer cell growth. In this study, an acidic pH-triggered drug-eluting nanocomposite (pH-DEN) including superparamagnetic iron oxide nanocubes and pH responsive synthetic peptides with lipid tails [octadecylamine p(API-L-Asp)(10)] was developed for magnetic resonance imaging (MRI)-monitored transcatheter delivery of sorafenib (the only FDA-approved systemic therapy for liver cancer) to HCC. The synthesized sorafenib-loaded pH-DENs exhibited distinct pH-triggered drug release behavior at acidic pH levels and highly sensitive MR contrast effects. In an orthotopic HCC rat model, successful hepatic IA delivery and distribution of sorafenib-loaded pH-DEN was confirmed with MRI. IA-delivered sorafenib-loaded pH-DENs elicited significant tumor growth inhibition in a rodent HCC model. These results indicate that the sorafenib pH-DENs platform has the potential to be used as an advanced tool for liver-directed IA treatment of unresectable HCC.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
